Massive global study digs into immunotherapy success in kidney cancer
NCT ID NCT05287464
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 15 times
Summary
This study gathers information from 1,220 people with advanced kidney cancer who received immunotherapy combinations as their first treatment. Researchers aim to find out which patients respond best and why, by looking at tumor genetics and immune cells. The goal is to improve future treatment decisions, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA ( MRCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale di Macerata, UOC Oncologia
RECRUITINGProvince of Macerata, Macerata, 62100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.